Former Bristol-Myers R&D chief signs on at VC firm

Former Bristol-Myers Squibb ($BMY) R&D chief Elliott Sigal is making the leap into venture capital. Sigal is joining New Enterprise Associates, where former MedImmune CEO David Mott has been leading the healthcare crew. Report